肾移植患者细小病毒B19感染的诊治进展  

Progress in diagnosis and treatment of parvovirus B19 infection in kidney transplant patients

作　　者：杨帆 倪兆慧 Yang Fan;Ni Zhaohui(Department of Nephrology,Renji Hospital,Clinical Research Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院肾脏科、上海交通大学医学院临床研究中心,200127

出　　处：《中华肾病研究电子杂志》2021年第2期109-112,共4页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：国家自然科学基金(81700586,81770666);上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划(SHDC2020CR3029B);上海市卫生和计划生育委员会综合医院中西医结合专项基金(ZHYY-ZXYJHZX-1-02);上海市卫生和计划生育委员会研究课题(201740037);上海市中西医临床协作试点建设项目[ZY(2018-2020)-FWTX-1001]。

摘　　要：细小病毒B19(PVB19)是在世界范围内广泛传播的人类普遍易感的一种DNA病毒,也是肾移植术后常见的感染病毒之一。它可引起多种临床疾病,与病毒特性和宿主免疫状态密切相关。目前国内外肾移植术后PVB19感染多以个案报道为主,缺乏统一的诊断标准,也尚无特异性抗病毒药物,主要治疗方法是静脉注射免疫球蛋白,但最佳剂量和疗程尚未确定。本综述通过回顾近年来PVB19感染诊治的相关文献旨在帮助临床医生提高对PVB19感染的认识,为及时诊断和治疗提供帮助。Parvovirus B19(PVB19)is a DNA virus that is universally susceptible to humans and is widely spread around the world.It is also one of the common infectious viruses after kidney transplantation.It can cause a variety of clinical diseases that are closely related to the virus characteristics and host immune status.At present,most PVB19 infections after renal transplantation at home and abroad were mainly cases reports,lacking both unified diagnostic standard and specific antiviral drugs.The main treatment of PVB19 infection is intravenous immunoglobulins,but the optimal dose and course of treatment have not yet been determined.This review aimed to help clinicians improve their understanding of PVB19 infection by reviewing relevant literature on the diagnosis and treatment of PVB19 infection in recent years,providing help for timely diagnosis and treatment.

关 键 词：细小病毒B19 肾移植 诊断与治疗 

分 类 号：R69[医药卫生—泌尿科学]